Table 4.
Base-Case Analysis Results
| RFC | FC | Incremental | |
|---|---|---|---|
| Mean life years | 5.82 | 5.60 | 0.21 |
| Mean life years progression-free | 3.30 | 2.56 | 0.74 |
| Mean life years in progression | 2.52 | 3.04 | −0.53 |
| Mean QALYs | 4.15 | 3.87 | 0.28 |
| Mean QALYs progression-free | 2.64 | 2.05 | 0.59 |
| Mean QALYs in progression | 1.51 | 1.83 | −0.32 |
| Mean total cost | £25,917 | £15,508 | £10,408 |
| Cost per life year gained | £48,772 | ||
| Cost per QALY gained | £37,665 |
FC, fludarabine and cyclophosphamide; QALY, quality-adjusted life year; RFC, rituximab, fludarabine, and cyclophosphamide.